ATE275397T1 - Zusammensetzungen, enthaltend blocker des renalen zelltransfers von l-dopa zur behandlung der parkinson-krankheit - Google Patents

Zusammensetzungen, enthaltend blocker des renalen zelltransfers von l-dopa zur behandlung der parkinson-krankheit

Info

Publication number
ATE275397T1
ATE275397T1 AT01931528T AT01931528T ATE275397T1 AT E275397 T1 ATE275397 T1 AT E275397T1 AT 01931528 T AT01931528 T AT 01931528T AT 01931528 T AT01931528 T AT 01931528T AT E275397 T1 ATE275397 T1 AT E275397T1
Authority
AT
Austria
Prior art keywords
dopa
blockers
parkinson
disease
treatment
Prior art date
Application number
AT01931528T
Other languages
English (en)
Inventor
Patricio Soares-Da-Silva
Original Assignee
Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portela & Ca Sa filed Critical Portela & Ca Sa
Application granted granted Critical
Publication of ATE275397T1 publication Critical patent/ATE275397T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01931528T 2000-03-14 2001-03-13 Zusammensetzungen, enthaltend blocker des renalen zelltransfers von l-dopa zur behandlung der parkinson-krankheit ATE275397T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0006063A GB2348371B (en) 2000-03-14 2000-03-14 Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
PCT/EP2001/002896 WO2001068065A2 (en) 2000-03-14 2001-03-13 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
ATE275397T1 true ATE275397T1 (de) 2004-09-15

Family

ID=9887552

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01931528T ATE275397T1 (de) 2000-03-14 2001-03-13 Zusammensetzungen, enthaltend blocker des renalen zelltransfers von l-dopa zur behandlung der parkinson-krankheit

Country Status (23)

Country Link
US (1) US20040242503A1 (de)
EP (1) EP1267853B1 (de)
JP (1) JP3677002B2 (de)
KR (1) KR100738746B1 (de)
CN (1) CN1262269C (de)
AR (1) AR035567A1 (de)
AT (1) ATE275397T1 (de)
AU (1) AU781280B2 (de)
BR (1) BR0109220A (de)
CA (1) CA2402712C (de)
CZ (1) CZ297123B6 (de)
DE (1) DE60105401T2 (de)
DK (1) DK1267853T3 (de)
ES (1) ES2228858T3 (de)
GB (1) GB2348371B (de)
HU (1) HUP0300130A3 (de)
MX (1) MXPA02009043A (de)
PL (1) PL359327A1 (de)
PT (1) PT1267853E (de)
RU (1) RU2266111C2 (de)
SI (1) SI1267853T1 (de)
TR (1) TR200402661T4 (de)
WO (1) WO2001068065A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
US7381772B2 (en) * 2003-12-12 2008-06-03 E. I. Du Pont De Nemours And Company Toughened poly(lactic acid) compositions
PT1751087E (pt) 2004-06-04 2012-09-10 Xenoport Inc Derivados de levodopa e as suas composições e utilizações
WO2006004552A1 (en) * 2004-07-07 2006-01-12 Kampavata Ab Transgenic non-human animal for use in research models for studying parkinson's disease
US8017649B2 (en) * 2005-03-11 2011-09-13 Howard Florey Institute Of Experimental Physiology And Medicine Flavonoid compounds and uses thereof
GB0505756D0 (en) * 2005-03-21 2005-04-27 Mars Uk Ltd Method
WO2007034024A2 (en) * 2005-09-21 2007-03-29 Orion Corporation Treatment of symptoms of parkinson' s disease
AU2006339607A1 (en) * 2005-12-02 2007-09-13 Sirtris Pharmaceuticals, Inc. Modulators of Cdc2-like kinases (Clks) and methods of use thereof
US7563821B2 (en) 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
CA2673336A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
WO2008079387A1 (en) 2006-12-21 2008-07-03 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
RU2009134137A (ru) * 2007-02-14 2011-03-27 Марс, Инкорпорейтед (Us) Нейрогенные соединения
BRPI0801239A2 (pt) * 2008-04-01 2009-11-17 Ache Lab Farmaceuticos Sa uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US9290445B2 (en) 2008-10-20 2016-03-22 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
US20100158829A1 (en) * 2008-12-24 2010-06-24 Conopco, Inc., D/B/A Unilever Method and Composition for Color Modulation
CN101856350A (zh) * 2009-04-13 2010-10-13 中国医学科学院药物研究所 黄芩素在制备预防和治疗帕金森病药物中的应用
WO2011056240A2 (en) 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
CN101797243B (zh) * 2010-03-23 2012-01-18 广东药学院 一种含有左旋多巴和冰片的组合物及其应用
KR101327936B1 (ko) * 2011-07-06 2013-11-13 한국식품연구원 옥시레스베라트롤 이민 유도체를 유효성분으로 함유하는 뇌신경보호 효과를 가지는 조성물
CN102755312A (zh) * 2012-07-16 2012-10-31 中国科学院大连化学物理研究所 具有黄酮骨架结构的化合物作为帕金森症治疗药物的应用
GB201302755D0 (en) 2013-02-15 2013-04-03 Mars Inc Horse supplement
CN103211832A (zh) * 2013-04-24 2013-07-24 无锡艾德美特生物科技有限公司 含杨酶苷或/和杨梅素的药物组合物及其在制备帕金森治疗药物中的用途
CN104116730A (zh) * 2013-04-26 2014-10-29 中国科学院大连化学物理研究所 二氢杨梅素作为活性成份在制备帕金森症治疗药物中的应用
KR101583399B1 (ko) * 2013-10-22 2016-01-08 충북대학교 산학협력단 아사리닌 또는 (-)-세사민을 함유하는 파킨슨병 예방 또는 치료용 약학조성물
EP3275433A1 (de) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Zusammensetzung mit verzögerter freisetzung mit mikronisiertem tolcapon
KR102681552B1 (ko) * 2016-09-27 2024-07-04 (주)아모레퍼시픽 소장 상피세포에서의 카테킨 흡수 증진제
CN111329853A (zh) * 2020-04-21 2020-06-26 遵义医科大学 一种治疗帕金森病的药物组合物及其应用和治疗帕金森病的药物
CN116908319A (zh) * 2023-05-31 2023-10-20 苏州和合医学检验有限公司 一种检测血液中苄丝肼浓度的方法
CN119192117B (zh) * 2024-10-31 2025-09-26 贵州医科大学 一种从马尾松松塔内分离出的黄酮类化合物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190672A (en) * 1978-09-01 1980-02-26 Stanley Fahn Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
JPS6450877A (en) * 1987-08-20 1989-02-27 Ichimaru Pharcos Inc Oxygen radical catching and removing agent
JPH035423A (ja) * 1989-06-01 1991-01-11 Ichimaru Pharcos Co Ltd フラボノイド含有過酸化脂質生成抑制剤
US5702752A (en) * 1996-03-13 1997-12-30 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
JPH09241637A (ja) * 1996-03-14 1997-09-16 Chugai Pharmaceut Co Ltd 活性酸素ラジカル除去用組成物およびその方法
GB9702310D0 (en) * 1997-02-05 1997-03-26 Univ Hertfordshire Invention
EP1032403B1 (de) * 1997-10-24 2012-05-02 John P. Blass Nahrungsergänzungsmittel für metabolische hirnleistungsstörungen
JPH11323326A (ja) * 1998-02-06 1999-11-26 Nagaoka Koryo Kk 活性酸素消去剤、皮膚保全剤および変色防止剤
FR2787319B1 (fr) * 1998-12-22 2002-06-14 Oreal Utilisation d'hydroxystilbenes pour la teinture, composition prete a l'emploi les contenant et procede de teinture
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
KR101098209B1 (ko) * 2002-01-28 2011-12-23 교와 핫꼬 기린 가부시키가이샤 운동성 질환에 걸린 환자의 치료 방법

Also Published As

Publication number Publication date
AU5828301A (en) 2001-09-24
US20040242503A1 (en) 2004-12-02
GB2348371A (en) 2000-10-04
PL359327A1 (en) 2004-08-23
WO2001068065A2 (en) 2001-09-20
GB2348371B (en) 2001-04-04
HUP0300130A2 (en) 2003-05-28
KR20030095184A (ko) 2003-12-18
AU781280B2 (en) 2005-05-12
SI1267853T1 (en) 2005-04-30
DE60105401D1 (de) 2004-10-14
CZ20023348A3 (cs) 2003-02-12
EP1267853A2 (de) 2003-01-02
EP1267853B1 (de) 2004-09-08
PT1267853E (pt) 2004-12-31
HUP0300130A3 (en) 2005-11-28
CN1262269C (zh) 2006-07-05
WO2001068065A3 (en) 2002-02-21
CN1429109A (zh) 2003-07-09
DE60105401T2 (de) 2005-10-13
RU2266111C2 (ru) 2005-12-20
DK1267853T3 (da) 2005-01-10
GB0006063D0 (en) 2000-05-03
WO2001068065A9 (en) 2002-07-18
JP3677002B2 (ja) 2005-07-27
BR0109220A (pt) 2003-03-18
ES2228858T3 (es) 2005-04-16
CZ297123B6 (cs) 2006-09-13
CA2402712C (en) 2005-05-17
KR100738746B1 (ko) 2007-07-12
JP2003526658A (ja) 2003-09-09
CA2402712A1 (en) 2001-09-20
TR200402661T4 (tr) 2004-11-22
AR035567A1 (es) 2004-06-16
MXPA02009043A (es) 2004-08-19

Similar Documents

Publication Publication Date Title
ATE275397T1 (de) Zusammensetzungen, enthaltend blocker des renalen zelltransfers von l-dopa zur behandlung der parkinson-krankheit
DK1112106T3 (da) Serotonerge 5HT2-agonister til behandling af glaukom
DK1173059T3 (da) Fremgangsmåde til forögelse af biologisk virkningsfuldhed af plantebehandlingssammensætninger
ATE305788T1 (de) (s,s)-reboxetin zur behandlung von inkontinenz
EE200200704A (et) Uued ühendid, meetod nende valmistamiseks ning nende kasutamine
EE200200470A (et) Uued ühendid, meetod nende valmistamiseks ning nende kasutamine
TR200003788A3 (tr) Yavas salimli oral dozaj bilesim.
MA26207A1 (fr) Compositions de traitement de l'eau.
DE10082139T1 (de) Zusammensetzung zur Behandlung von Reibungspaaren
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
NO20031273L (no) Substituerte kanelsyreguanidiner, fremgangsmåte for deres fremstilling, deres anvendelse som legemiddel og legemiddel som inneholder de samme
DK1309545T3 (da) Fremgangsmåde til fremstilling af alkylarylsulfonater
DZ3001A1 (fr) Sel de potassium d'oméprazole-(S).
TNSN01131A1 (fr) Derives de phenoxybenzylamine nouveaux, procede pour leur preparation et compositions les contenant.
ID28601A (id) Proses penyiapan senyawa-senyawa 1,4-dihidropiridin
DE60005462D1 (de) Tintenzusammensetzungen enthaltend 1,3,5-Trioxan
AU5735701A (en) Seed treatment composition
EE200200697A (et) Uued ühendid, meetod nende valmistamiseks ning nende kasutamine
BRPI0414678A (pt) forma polimórfica de 3-fenil sulfonil-8-piperazin-1-il quinolina
DE60002254T2 (de) Verfahren zur Herstellung von 4,6-diaminoresorcin
FR2894143B1 (fr) Composition a liberation prolongee de l'actif, son procede de preparation et son utilisation.
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
BR0012043B1 (pt) composiÇço de tratamento de cabelo.
FR2815332B1 (fr) Devidoir suspendu, notamment pour cultures
DK1373232T3 (da) Fremgangsmåde til fremstilling af N-substituerede 2,6-dialkylmorpholiner

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1267853

Country of ref document: EP

REN Ceased due to non-payment of the annual fee